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Abstract: Denture-related stomatitis (DRS) is the most common condition affecting removable-denture wearers, and 
Candida albicans the most frequent pathogenic agent. Systemic antifungal treatment is indicated but recurrences are fre-
quent. The aim of this study was to characterize the oral load, fluconazole susceptibility profile and genotypic variability 
of oral C. albicans isolates from patients with DRS before (T0), immediately after fluconazole treatment (Tat) and after  
6-months follow-up (T6m). Eighteen patients presenting DRS and treated with fluconazole were followed at the Faculty 
of Dentistry of Oporto University. Seventy C. albicans isolates were obtained and identified using standard cultural and 
biochemical multi-testing. Fluconazole susceptibility was tested by E-test
®
. Microsatellite-primed PCR was performed to 
assess the genotypic variability of C. albicans isolates. The patients’ mean age was 58.0±3.2 years, and 55.6%/44.4% had 
total/partial dentures. Before treatment, 22.2%, 44.4% and 33.3% of the patients presented DRS type I, II or III, respec-
tively. Fluconazole treatment healed or improved DRS in 77.8% of the patients, accompanied by an 83.5% reduction in 
oral C. albicans load. However, after 6-months, oral C. albicans load increased significantly and DRS severity was simi-
lar to the one observed before treatment. Moreover, the prevalence of patients presenting fluconazole resistant isolates of 
C. albicans increased significantly throughout the study: T0-5.6%, Tat-10.0% and T6m-42.9%. A change in the genotypic 
variability of C. albicans isolates was also verified, being mostly associated to fluconazole susceptibility profile change. 
In conclusion, fluconazole presents a good short-term DRS treatment efficiency, but may be associated to a long-term 
emergence of C. albicans fluconazole resistance.  
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INTRODUCTION 
Denture-related stomatitis (DRS) is defined as an in-
flammatory process of the oral mucosa underlying a remov-
able, partial or total, dental prosthesis. In patients with re-
movable prostheses, the mean prevalence of DRS is 50%  
[1, 2]. Aetiological factors in DRS include the trauma caused 
by an ill-fitting denture, lack of oral and prosthesis hygiene 
and a favourable environment for the proliferation of micro-
organisms [3]. Although bacterial infection, mechanical irri-
tation, and allergic reaction have been proposed as possible 
causes of DRS, infection with Candida species is often im-
plicated [1, 2, 4]. 
Candida spp. are oral commensals present in up to 90% 
of healthy persons and Candida albicans (C. albicans) is the 
most frequent colonizer fungi [5-7]. Previous studies from 
our group showed that DRS is clearly associated with oral 
infection by yeasts, mainly C. albicans [1], although the 
same genotype may be found both in DRS patients and in  
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healthy controls [8]. Although DRS is not a particularly se-
vere pathology, it may be a portal of entry for further infec-
tions mainly in susceptible patients [1, 2]. 
There is clear evidence that the management of Candida-
associated denture stomatitis is complex due to its multifac-
torial aetiology [9-11]. Current treatment includes control of 
denture plaque, and, with patient compliance, some rest pe-
riods of denture wearing in addition to the use of antimicro-
bial agents [12, 13]. Topical antifungal drugs, such as nys-
tatin, amphotericin B, and miconazole have proved to be 
effective in DRS improvement [14-16]. However, recurrence 
rates are high and treatment regimens tend to be extended 
[17, 18]. The systemic triazoles, such as fluconazole, are 
currently the first therapeutic choice for the treatment of this 
infection [19, 20], although progressive recolonization of the 
palate and the denture fitting surface by yeast, together with 
a high rate of clinical relapse and recurrence after therapy, 
have also been reported [14, 21]. So, the aim of this study 
was to characterize during a 6-months period the oral load, 
fluconazole susceptibility profile and genotypic variability of 
oral C. albicans isolates from DRS patients treated with flu-
conazole therapy. 
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MATERIAL AND METHODS 
Study Design and Patient Selection 
Twenty-one patients wearing polymethylmethacrylate 
maxillary removable prosthesis, with clinical diagnosis of 
DRS, followed at the outpatient clinic of the Faculty of Den-
tistry of Oporto University were randomly selected. Patients 
were assessed clinically and saliva samples were collected 
for microbiological analysis at the first clinical evaluation 
and diagnosis (T0), after fluconazole treatment (Tat) and 
after a 6-month follow-up period (T6m). Fluconazole was 
prescribed systemically (Fluconazol 50mg, Diflucan
®
 Pfizer) 
for 15 days to all patients. After this period, systemic flu-
conazole was prescribed for further 15 days only to patients 
who did not improve clinically from DRS.  
Ethics Committee of the Faculty of Dentistry of Oporto 
University reviewed and approved this study. All partici-
pants were recruited voluntarily after receiving detailed in-
formation on the study protocol. Free and written informed 
consent was obtained from all participants, according to the 
Helsinki Declaration.  
Clinical Oral Evaluation 
To identify and characterize the different DRS presenta-
tions, the Newton classification was used: DRS type I (local-
ized inflammation or hyperaemia points), DRS type II (dif-
fuse erythema) and DRS type III (palate papillary hyperpla-
sia) [22].  
Denture hygiene was assessed by modification of the 
Tarbet index [1, 4, 23].
 
The patients were classified accord-
ing to the total denture surface covered with microbial 
plaque evaluated by a dental plaque disclosing solution 
(Dento-plaque
®
, Pierre-Fabre Dermo-Cosmetique) in the 
following groups: poor denture hygiene, >76%; insufficient 
denture hygiene, 26 to 75%, and good denture hygiene,  
< 25%.  
Additionally, before the oral clinical evaluation, unstimu-
lated whole saliva was collected in a sterile container at least 
2h after eating, tooth brushing, mouth washing or smoking.  
Candida albicans Isolation and Quantification 
Saliva samples from all patients were serially diluted 
with 0.9% sterile NaCl solution until 10
-1
 and immediately 
plated in triplicate in a selective and differential culture me-
dium, CHROMagar CandidaTM
®
 (Becton Dickinson, 
Sparks, USA). Afterwards, plates were incubated aerobically 
for 48h at 37°C. The total number of green-pigmented colo-
nies (Candida albicans) were counted and isolated. The 
lower limit of detection was 1CFU/mL. C. albicans isolates 
were identified based on germ-tube formation, chlamy-
dospore production and carbohydrate assimilation using the 
ID 32C system (BioMerieux, Marcy l'Etoile, France). The 
yeasts identified as C. albicans were also screened for their 
ability to grow on Sabouraud dextrose agar at 45ºC for 48h 
and xylose assimilation, to distinguish from C. dubliniensis 
[24]. Several colonies of each different phenotype were se-
lected and kept frozen at -70ºC, in sterile water with 30% 
glycerol. Prior to testing, the yeasts were subcultured in 
Sabouraud dextrose agar (BioMerieux, Marcy l'Etoile, 
France) and incubated at 37ºC for two days. A total of 70 C. 
albicans isolates were obtained at T0, Tat and T6m from all 
patients. C. dubliniensis FFUL 21 and Candida albicans 
ATCC 90028 were used as internal controls for the identifi-
cation tests. 
Antifungal Susceptibility Testing 
Susceptibility testing to fluconazole was performed by 
Etest
®
 (BioMerieux, Marcy l'Etoile, France), according to 
the manufacturer’s instructions. C. albicans isolates were 
classified accordingly to the proposed in vitro breakpoints to 
fluconazole: susceptible, minimal inhibitory concentration 
(MIC) 8mg/L; susceptible-dose dependent (S-DD), MIC 
between 16 to 32mg/L; and resistant, MIC 64mg/L.  
Microsatellite-Primed PCR 
For microsatellite-primed PCR genomic DNA was ex-
tracted in accordance with Treco [25]. Nucleic acid purity 
and concentration were assessed by spectroscopy at 260 and 
280nm. A single repeat sequence of the phage M13, 5’-GAG 
GGT GGC GGT TCT-3’ was used in the microsatellite-
primed PCR experiments, because the array of DNA frag-
ments presented high intensity bands and identical patterns 
of DNA fragments were detected with replicate samples, 
showing to be the best primer tested [26]. Synthetic oligode-
oxyribonucleotide molecules were prepared by Oligo-
Express (Paris, France). Amplification reactions were per-
formed in volumes of 50mL containing 25ng template DNA, 
10mmol/L Tris-HCl (pH 8.3), 50mmol/L KCl, 4mmol/L 
MgCl2, 200mmol/L of each dNTPs, 1 mmol/L of primer, and 
2.5U Taq DNA polymerase. Except for dNTPs, obtained 
from Amersham Pharmacia Biotech (Uppsala, Sweden), all 
PCR reagents were purchased from Perkin Elmer Corp., Ap-
plied Biosystems (New Jersey, USA). The samples were 
amplified in a Biometra T1 termocycler (Göttingen, Ger-
many), and the thermal cycling parameters were an initial 
denaturation at 95ºC for 3min, followed by 35 cycles of de-
naturation at 95ºC for 45s, annealing at 46ºC for 40s, and 
extension at 72ºC for 30s with final extension at 72ºC for 5 
minutes. PCR products were analysed by electrophoresis 
with agarose gel stained with ethidium bromide. DNA Lad-
der and pBR322 DNA-BstNI digest (New England Biolabs, 
Beverly, Mass.) were used as molecular size standards. To 
ensure the reproducibility of the results, reference strains 
were systematically run as controls together with negative 
controls (no DNA). The profiles for each isolate were com-
pared visually with identical band patterns deemed to repre-
sent the same genotype.  
Statistical Analysis 
The statistical analysis was performed using IBM
®
 
SPSS
®
 version 19.0 (Statistical Package for Social Sciences). 
The categorical variables were described through absolute 
and relative frequencies (%) and analysed by Chi-square 
independence test. Continuous variables were described us-
ing mean ± standard error (SEM) and analysed by Anova 
followed by students’ t-test. Statistical significance was as-
sumed when the p values were less than 0.05. 
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RESULTS 
The first clinical evaluation and diagnosis (T0) was per-
formed to 21 patients presenting a mean age of 57.6 years 
with a standard error of 3.1 years; 28.6% were males and 
71.4% were females. Three patients (14.3%) did not con-
clude the study due to different reasons – death, hospitaliza-
tion and unknown whereabouts - and were excluded thus 
from the analysis. The characterization of the group of par-
ticipants followed during the 6-month period is shown in 
Table 1 (n=18). All patients had dentures of polymeth-
ylmethacrylate resin. At the time of the first clinical evalua-
tion most of the patients presented DRS type II and insuffi-
cient denture hygiene (Table 1). 
 
Table 1.  Characterization of patients with denture-related 
stomatitis (DRS) regarding age, denture type and 
denture hygiene at the time of first diagnosis (T0). 
 
DRS patients 
(n=18) 
Age, years 58.0±3.2 
Gender, male / female 33.3% / 66.6% 
Total / partial denture 55.6% / 44.4% 
DRS type I / II / III 22.2% / 44.4% / 33.3% 
Poor / insufficient / good denture hygiene 16.7% / 66.7% / 16.7% 
Values are mean±sem or prevalence (%).  
 
After 15 days of fluconazole treatment, 55.6% of the pa-
tients healed or improved DRS (Table 2). The remaining 
44.4% presented DRS type I or II, evenly. These patients 
were prescribed further 15 days of fluconazole treatment. 
Half of the patients with 30 days of fluconazole treatment 
healed or improved DRS. In total, fluconazole therapy 
healed or improved DRS in 77.8% of the patients, regardless 
of the duration of the treatment. After the fluconazole treat-
ment, 38.9% of the patients presented no clinical evidence of 
DRS, 44.4% presented DRS type I, 16.7% presented DRS 
type II, and no patient presented DRS type III (Fig. 1). After 
the 6-months follow up period, the DRS worsened in most of 
the evaluated patients and DRS severity was similar to that 
observed before treatment (Fig. 1). The prevalence of DRS 
type changed significantly throughout the study (Fig. 1, 
p=0.001). 
 
Table 2.  Fluconazole response of the followed up patients. 
Fluconazole 
treatment period 
Healed Improved 
Not  
improved 
15 days 27.8% 27.8% 44.4%* 
Plus 15 days 11.1 % 11.1% 22.2% 
*These patients did further 15 days of fluconazole therapy. 
 
At T0, the oral C. albicans prevalence in the evaluated 
patients was 94.4% and the mean load was 
139.9±27.9CFU/mL of saliva. Fluconazole treatment re-
duced oral C. albicans prevalence and load in saliva, but at 
T6m the C. albicans prevalence increased, as did the C. albi-
cans load (Fig. 2). The oral C. albicans prevalence profile 
differed significantly throughout the study (p=0.015). 
 
 
Fig. (1). Denture-related stomatitis (DRS) type at the time of sto-
matitis diagnosis (T0), after treatment (Tat) and 6-months after 
diagnosis (T6m). Bars represent prevalence.  
 
At T0, the fluconazole susceptible dose-dependent and re-
sistant isolates of C. albicans represented 5.6% each, 
whereas the susceptible isolates represented 88.9% (Fig. 3). 
After the 6-month follow-up period the C. albicans resistant 
isolates represented 42.9%, whereas the susceptible isolates 
represented 57.1% (Fig. 3). 
The analysis of genotypic variability of C. albicans iso-
lates, using primer M13, generated profiles with 6 to 14 
bands varying between 400 and 1,800bp. From all evaluated 
patients that presented C. albicans counts in more than in 
one evaluation point, 42.9% showed a change in genotypic 
variability of C. albicans isolates throughout the study. Two 
examples of C. albicans profile change from T0 to T6m are 
shown in Fig. (4). Patient 1 presents two different genetic 
profiles, whereas patient 2 presents 3 different C. albicans 
genetic profiles. Identical profiles were obtained for all repli-
cate samples, confirming the high reproducibility of this 
method. From this group of patients presenting C. albicans 
genotypic variability of M13 primer throughout the study, 
83.3% had at least one C. albicans isolate resistant to flu-
conazole. 
DISCUSSION 
The present work intended to evaluate the effect of flu-
conazole treatment on short-term and long-term clinical de-
velopment of DRS and C. albicans oral colonization profile.  
Several factors may contribute to the onset and worsen-
ing of DRS, namely poor denture hygiene, continuous wear-
ing of removable dentures, accumulation of denture plaque, 
bacterial and yeast contamination of denture surface and 
mucosal trauma due to poor-fitting dentures. In the present 
study each patient was his own control, since patients were 
evaluated before and after fluconazole treatment. Changes 
were not observed throughout the study in denture substitu-
tion or adjustment, denture hygiene promotion and denture 
daily wearing period, factors that could influence DRS pro-
gression besides fluconazole therapy. 
There is a large body of evidence indicating that Candida 
is able to adhere to acrylic resin dentures, namely to 
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Fig. (2). Oral Candida albicans load and prevalence at the time of stomatitis diagnosis (T0), after treatment (Tat) and 6-months after diagno-
sis (T6m). Left bars represent means and error bars represent SD. p values were calculated using Anova (p=0.00038) followed by students’ t-
test. *p<0.05, significantly different from T0; 
#
p<0.05, significantly different from Tat. Right bars represent prevalence. 
 
 
Fig. (3). Prevalence of fluconazole susceptibility profile of Candida albicans isolates at the time of stomatitis diagnosis (T0), after treatment 
(Tat) and 6-months after diagnosis (T6m). Bars represent prevalence. 
 
polymethylmethacrylate – PMMA, forming a biofilm [27, 
28]. As expected and in agreement with previous reports, 
denture wearer patients presented high rates of C. albicans 
oral colonization (94.4%) at the time of the first clinical 
evaluation (T0) [29-31]. This denture biofilm provides a 
source of microorganisms that is continuously exposed to the 
oral mucosa. This is the first step that may lead to the devel-
opment of the infectious process and that may ultimately 
result in varying degrees of denture stomatitis of the adjacent 
mucosa [29, 32]. 
As expected, fluconazole treatment significantly reduced 
the oral C. albicans colonization and greatly improved the 
severity of DRS in the studied population [29, 33, 34]. How-
ever, these effects were observed only immediately after 
treatment (Tat). After the 6-month follow-up period (T6m), 
either oral C. albicans colonization or DRS severity profiles 
were similar to the ones observed before fluconazole treat-
ment, revealing a good short-term but not a good long-term 
fluconazole DRS treatment efficiency. This fact probably 
reflects recontamination by residual yeasts that are present 
on the denture surfaces [29]. 
 
Fig. (4). Genotypic variability of Candida albicans isolates from 
two different patients studied by MSP-PCR with the primer M13 at 
the time of DRS diagnosis (T0), and 6-months after diagnosis 
(T6m). Molecular size markers used were DNA Ladder (m1) and 
pBR322 DNA-BstNI digest (m2). 
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Additionally, the C. albicans oral population appear to 
change over time due to the increase of C. albicans isolates 
resistant to fluconazole 6-months after therapy. This hy-
pothesis was reinforced by the high rate of genetic variability 
found in C. albicans isolates within each patient when iso-
lates collected before and 6-months after fluconazole treat-
ment were compared. Notwithstanding, no specific C. albi-
cans resistant genes were analysed, such as the efflux pumps 
[35]. Increasing scientific literature addresses this phenome-
non of antimicrobial resistance induced by therapeutic treat-
ment regarding non-oral infections [36]. In oral cavity, an-
timicrobial resistance is still scarce; however, dental medical 
doctors should be aware of its increasing importance and 
future implication. Despite the good short-term fluconazole 
efficiency in the treatment of DRS, the fluconazole-
generalized prescription should be avoided to reduce the 
emergence of resistant strains of C. albicans and the increas-
ing episodes of DRS recurrences. Therefore, other therapeu-
tic or prevention strategies should be implemented before 
fluconazole is recommended, namely denture disinfection 
together with denture hygiene education and surveillance, 
denture adjustment or replacement [20]. In addition, new 
developments related to denture materials are focusing on 
means to reduce development of adherent biofilms. These 
developments may be valuable in reducing yeast coloniza-
tion, and could lead to reductions in denture stomatitis with 
appropriate denture hygiene [29, 37]. 
Nevertheless, some clinical scenarios may require flu-
conazole use, namely in DRS in immunosuppressed patients 
at a risk of a systemic infection or patients with persistent 
severe symptomatologic DRS [20]. 
CONCLUSION 
In conclusion, fluconazole presents a good short-term, 
but not a good long-term, DRS treatment efficiency. Also 
fluconazole treatment of DRS may be associated to a long-
term emergence of oral C. albicans fluconazole resistance. 
Other therapeutic or prevention strategies should be imple-
mented before fluconazole is prescribed, namely denture 
disinfection, together with denture hygiene education and 
surveillance, as well as denture adjustment or replacement. 
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